HIFU appears to offer cancer control in localized PCa patients

Article

Transrectal high-intensity focused ultrasound (HIFU) appears to offer long-term cancer control in patients with low- or intermediate-risk localized prostate cancer, according to a multicenter study published in the Nov. 5, 2007, online edition of European Urology.

Transrectal high-intensity focused ultrasound (HIFU) appears to offer long-term cancer control in patients with low- or intermediate-risk localized prostate cancer, according to a multicenter study published in the Nov. 5, 2007 online edition of European Urology.

A total of 140 patients (mean age, 69 years) with T1–T2 prostate cancer, a PSA <15.0 ng/mL, and a Gleason score  ≤7 were treated with prototypes or first-generation HIFU devices (Ablatherm, EDAP TMS, Lyon, France) between October 1997 and August 2001. Mean follow-up was 6 years.

Control prostate biopsies were negative in 86.4% of patients, according to senior author Albert Gelet, MD, of Edouard Herriot Hospital in Lyon. Median PSA of 0.16 ng/mL (range, 0-9.1 ng/mL) was achieved at a mean of 4.9 months. A PSA nadir of ≤0.5 ng/mL was recorded in 68.4% of patients. The actuarial biochemical failure-free survival rates at 5 and 7 years were 77% and 69%, respectively; actuarial disease-free survival rates at 5 and 7 years were 66% and 59%, respectively.

Related Videos
Dr. Christopher Wallis in an interview with Urology Times
Randall A. Lee, MD, answers a question during a Zoom video interview
Edward M. Schaeffer, MD, PhD, answers a Zoom video interview question
Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
James Ferguson III, MD, PhD, answers a question during a Zoom video interview
Nicholas L. Kavoussi, MD, answers a question during a Zoom video interview
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Related Content
© 2023 MJH Life Sciences

All rights reserved.